These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 6086215)
21. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination. Nanetti A; La Placa M J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765 [TBL] [Abstract][Full Text] [Related]
22. [In vitro evaluation of the activity and interactions of cefotaxime and its metabolite desacetylcefotaxime against strains of enterobacteria, staphylococci and Bacteroides fragilis isolated from hospital infections]. Pitzus E G Ital Chemioter; 1989; 36(1-3):57-64. PubMed ID: 2488914 [TBL] [Abstract][Full Text] [Related]
23. The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs. Jones RN J Antimicrob Chemother; 1984 Sep; 14 Suppl B():39-43. PubMed ID: 6094461 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms. Aldridge KE; Weeks LS; Stratton CW; Sanders CV Diagn Microbiol Infect Dis; 1989; 12(2):165-70. PubMed ID: 2752714 [TBL] [Abstract][Full Text] [Related]
25. [Comparison of antimicrobial activity and stability to beta-lactamases of cefoperazone, cefotaxime, lamoxactam and ceftriaxon]. Baumgärtner M; Grehn M; Wundt W Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):208-21. PubMed ID: 6289564 [TBL] [Abstract][Full Text] [Related]
26. The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides. Seibert G; Limbert M; Winkler I; Dick T Infection; 1983; 11(5):275-9. PubMed ID: 6315595 [TBL] [Abstract][Full Text] [Related]
27. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Jones RN; Barry AL; Thornsberry C; Wilson HW Antimicrob Agents Chemother; 1981 Dec; 20(6):760-8. PubMed ID: 6275785 [TBL] [Abstract][Full Text] [Related]
28. Cefoxitin sensitivity as a marker for inducible beta-lactamases. Moritz VA; Carson PB J Med Microbiol; 1986 May; 21(3):203-7. PubMed ID: 3486293 [TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group. Cornick NA; Gorbach SL Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498 [TBL] [Abstract][Full Text] [Related]
30. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria. Devlin HR; Boskovski L Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488 [TBL] [Abstract][Full Text] [Related]
31. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains]. Mascellino MT; Prignano G; Iegri F; Lorenzi A Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234 [TBL] [Abstract][Full Text] [Related]
32. In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin. Scully BE; Jules K; Neu HC Antimicrob Agents Chemother; 1983 Jun; 23(6):907-13. PubMed ID: 6311090 [TBL] [Abstract][Full Text] [Related]
33. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160 [TBL] [Abstract][Full Text] [Related]
34. [Bacteriological and clinical studies on cefotaxime in obstetrics and gynecology (author's transl)]. Ninomiya K; Hasegawa Y; Hamatani K; Nishio T Jpn J Antibiot; 1981 Apr; 34(4):507-14. PubMed ID: 6270399 [TBL] [Abstract][Full Text] [Related]
35. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus. Canawati HN Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357 [TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro studies on cefotaxime and desacetylcefotaxime. Selwyn S; Bakhtiar M Drugs Exp Clin Res; 1986; 12(12):953-65. PubMed ID: 3494587 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin. Schmalreck AF; Wildfeuer A Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754 [TBL] [Abstract][Full Text] [Related]
38. Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and Enterobacteriaceae. Hansen BG; Søgaard P Acta Pathol Microbiol Immunol Scand B; 1985 Jun; 93(3):243-7. PubMed ID: 3875967 [TBL] [Abstract][Full Text] [Related]
39. [beta-lactamase-producing activity and antimicrobial susceptibility of major pathogenic bacteria isolated from clinical samples. Japan beta-lactamase Research Group]. Oguri T; Igari J; Hiramatsu K; Watanabe A; Inoue M; Abe M; Yamane N; Aihara M; Hashimoto H; Jpn J Antibiot; 2002 Sep; 55 Suppl A():1-28. PubMed ID: 12599526 [TBL] [Abstract][Full Text] [Related]
40. [MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis]. Deguchi K; Fukuyama S; Nishimura Y; Nishike A; Fukumoto T; Oda S; Sato S; Matsumoto Y; Ikegami R; Yokota N Jpn J Antibiot; 1984 Sep; 37(9):1701-13. PubMed ID: 6096585 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]